Bausch Health Companies Inc. (BHC.TO)
| Previous Close | 9.22 |
| Open | 8.99 |
| Bid | 8.92 x 0 |
| Ask | 8.93 x 0 |
| Day's Range | 8.79 - 9.00 |
| 52 Week Range | 8.79 - 15.43 |
| Volume | |
| Avg. Volume | 419,726 |
| Market Cap | 3.279B |
| Beta (5Y Monthly) | 0.90 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.69 |
| Earnings Date | Aug 01, 2024 - Aug 05, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Nov 10, 2010 |
| 1y Target Est | 13.28 |
ACCESSWIRESalix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024
LAVAL, QC / ACCESSWIRE / May 17, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today announced that they will be presenting data from its Phase 2 trial evaluating Amiselimod ...
ACCESSWIREBausch Health Announces 2024 Annual Meeting of Shareholder Results
LAVAL, QC / ACCESSWIRE / May 15, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the results of its 2024 annual meeting of shareholders. Annual Meeting Results The 10 directors nominated at the Company's 2024 annual meeting ...
- ACCESSWIRE
Bausch Health Announces Updates Related to Norwich XIFAXAN Matters
LAVAL, QC / ACCESSWIRE / May 14, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business Salix Pharmaceuticals, today announced certain updates related to its litigation with Norwich Pharmaceuticals, Inc. With respect ...
